CPT® Code 45380

Quick Reference:

• What 45380 means: Flexible colonoscopy with biopsy, single or multiple. The code represents the endoscopic procedure and the act of obtaining one or more tissue samples for pathology during the same session. Do not report 45380 multiple times for multiple biopsy sites in one colonoscopy.
• “Complete colonoscopy” matters: A full colonoscopy generally means insertion to the cecum (or colon–small intestine anastomosis in post-surgical anatomy). When the exam is not completed to the cecum, correct reporting depends on whether a therapeutic intervention occurred before termination and on payer rules for discontinued/reduced services.
• Screening vs diagnostic/therapeutic: If the intent is screening but a biopsy is performed, the service becomes diagnostic/therapeutic from a CPT perspective (use 45380), while coverage processing may still follow preventive rules when you apply the appropriate payer-specific modifier and screening diagnosis logic. Medicare guidance on “screening converted to diagnostic/therapeutic” is the practical anchor.
• Bundling and distinct lesions: Under NCCI principles, the base diagnostic colonoscopy is included in more extensive colonoscopy services. When biopsy is performed on a separate lesion from a polypectomy or other higher service in the same session, a distinctness modifier may be required if the code-pair edit allows it. NCCI guidance is the primary reference for bundling and modifier use in this family.
• Preventive modifiers: For commercial plans, modifier 33 may be used to indicate preventive intent for eligible screening services when a biopsy occurs. For Medicare screening colonoscopy converted to diagnostic/therapeutic, modifier PT is the recognized mechanism described in GI coding guidance and MAC materials. Apply the modifier to the colonoscopy code(s) that represent the converted service per payer direction.
• Payment mechanics (important for reconciliation): Colonoscopy codes are subject to Medicare’s multiple endoscopy payment logic; claims may not pay “50% of the second procedure” the way other multiple-procedure families do. Do not use payment outcomes as a proxy for coding correctness—validate coding by documentation and policy, then reconcile payment to endoscopy rules.
• Medical necessity and diagnosis selection: ICD-10 selection should reflect the reason for the exam (symptom/abnormal test/history) and the reason for biopsy (finding/concern). Payers commonly adjudicate diagnostic colonoscopy claims against coverage logic or medical policies; overly vague diagnoses increase denial risk.

CPT 45380 is one of the highest-volume diagnostic colonoscopy codes because biopsy is a common endpoint of lower GI evaluation and surveillance.

Most claim risk does not come from the biopsy itself, it comes from

1. mismatching the billed code to what was performed (biopsy vs removal),
2. failing to support “complete colonoscopy” versus discontinued/reduced services,
3. screening-to-diagnostic conversions processed without the correct modifier logic, and
4. unbundling errors when multiple colonoscopy interventions occur in the same session.

This 2026 guide is written to be payer-realistic: it aligns CPT intent, documentation standards, CMS/NCCI bundling principles, and Medicare/plan processing behavior into a defensible coding approach.

1. Definition & Procedure Scope

CPT 45380 describes a flexible colonoscopy performed with biopsy, “single or multiple.” In operational terms, the endoscopist advances a colonoscope through the colon (with the clinical intent of examining the colon) and obtains one or more tissue samples for diagnostic histopathology during the same procedure session. The code represents the endoscopic service and the biopsy acquisition work; pathology interpretation is reported separately by the pathology provider/lab using pathology CPT codes (not part of 45380).

A key compliance point is that “single or multiple” is inherent in the descriptor: multiple biopsy specimens obtained during the same colonoscopy do not justify multiple units of 45380. Coding accuracy depends on identifying what intervention was actually performed at each lesion. If a lesion is removed (e.g., snare polypectomy), the removal code generally represents the service for that lesion; biopsy performed on the same lesion before removal is typically considered part of the more extensive removal service. Separate reporting of 45380 may be appropriate only when the biopsy is on a distinct lesion/site and the applicable code-pair rules allow separate reporting with a modifier when documentation supports distinctness. NCCI policy is the primary framework for these determinations.

“Colonoscopy” is also a scope-defined service: the documentation must establish the extent of insertion (e.g., to the cecum or surgical anastomosis) and any reason for an incomplete exam. GI professional coding materials emphasize the need to document extent and findings clearly because that is how payers and auditors validate that the billed code family (colonoscopy vs limited lower endoscopy) was actually performed.

Boundary rule (high yield): If the documentation supports that a polyp or lesion was fully removed by a defined technique (e.g., snare), choose the removal code for that lesion. Do not “double bill” biopsy plus removal on the same lesion. Reserve 45380 (with an appropriate distinctness modifier when required) for biopsy performed on a different lesion/site than the lesion treated by the more extensive intervention, consistent with NCCI principles.

flowchart TD
    A[Colonoscopy with Tissue Intervention] --> B{Was a biopsy performed?}
    B -->|No| C[Report 45378 - Diagnostic colonoscopy]
    B -->|Yes| D{Was a lesion also removed by snare?}
    D -->|No| E[Report 45380 - Colonoscopy with biopsy]
    D -->|Yes| F{Biopsy on same lesion as snare removal?}
    F -->|Yes| G[Report removal code only - Do NOT add 45380]
    F -->|No| H[Report removal code + 45380 with Modifier 59]
    E --> I{Was this a screening colonoscopy?}
    H --> I
    I -->|No| J[Submit with diagnostic ICD-10]
    I -->|Yes| K{Payer type?}
    K -->|Medicare| L[Append Modifier PT + screening Dx]
    K -->|Commercial| M[Append Modifier 33 + screening Dx]

2. Appropriate Clinical Use & Indications

CPT 45380 is used when biopsy is clinically necessary to establish or confirm a diagnosis, characterize mucosal disease, or evaluate suspicious lesions identified during colonoscopy. In practice, the most common indication categories fall into: (a) symptom-driven diagnostic evaluation, (b) abnormal test findings, and (c) surveillance contexts where biopsy is clinically appropriate. Coverage and medical necessity expectations vary by payer, but large payer medical policies and Medicare screening/diagnostic conversion rules shape common claims behavior.

2.1 Symptom-driven diagnostic evaluation

• Overt or occult GI bleeding / anemia evaluation: Colonoscopy with biopsy may be indicated to evaluate bleeding sources (e.g., malignancy suspicion, inflammatory changes, ulceration) and to sample tissue when endoscopic appearance raises concern. When biopsy is performed to characterize an abnormal area thought to contribute to bleeding or anemia, 45380 accurately describes the service. Medicare screening coverage rules are separate from medical necessity rules for symptomatic cases; symptomatic cases are generally processed as diagnostic/therapeutic.
• Chronic diarrhea / suspected inflammatory or microscopic colitis: Biopsy may be taken even when mucosa appears normal to evaluate for microscopic colitis or other histologic diagnoses, and multi-site sampling is common. Payer medical policies often describe colon biopsy as medically necessary for specific diagnostic questions, and GI society materials emphasize documentation of indication and sampling strategy.
• Suspected inflammatory bowel disease (IBD) and mucosal assessment: Biopsy supports diagnosis and disease activity/extent characterization in IBD. In IBD contexts, biopsies may be obtained from multiple segments to support diagnosis or dysplasia assessment. Documentation should connect the biopsy to the clinical question and endoscopic findings (even if subtle).

2.2 Abnormal tests or imaging findings

• Positive stool-based screening tests (FIT/FOBT) or other abnormal findings: When colonoscopy is performed after a positive test and biopsy is taken of an abnormality found, 45380 may be appropriate depending on the intervention actually performed (biopsy vs complete removal). If the lesion is removed, removal codes apply; if tissue is sampled without complete removal, biopsy coding applies. Preventive processing rules may apply when the colonoscopy was performed as a screening benefit follow-up under plan policy; documentation should clearly explain the clinical pathway.
• Suspicious mass/lesion requiring histologic confirmation: When the endoscopist biopsies a suspicious lesion (e.g., possible malignancy) rather than removing it endoscopically, 45380 is a common correct procedure code. The biopsy location and rationale should be explicit because this is a high-scrutiny claim pattern in audits and denials.

2.3 Surveillance contexts

• Post-polyp or high-risk surveillance: Surveillance colonoscopies may become diagnostic/therapeutic when a biopsy is performed. For Medicare beneficiaries, certain high-risk surveillance pathways are treated within screening coverage frameworks (frequency depends on risk category). If a screening/surveillance colonoscopy leads to biopsy, Medicare processing uses modifier PT to identify conversion to diagnostic/therapeutic.
• Post-cancer resection surveillance: Biopsy may be taken of suspicious mucosal changes, anastomotic sites, or new lesions identified during surveillance. Coding depends on the intervention and medical necessity documentation. Payer medical policies may treat timing/frequency as a utilization checkpoint, making clarity of history and rationale important.

When not to use 45380: Do not report 45380 when no biopsy is performed. Do not report 45380 in place of a polypectomy/removal code when the lesion is fully removed by a defined technique. And do not report multiple units of 45380 for multiple biopsy sites within the same colonoscopy. When multiple interventions occur, choose the correct codes for each distinct lesion or service, then apply bundling/modifier rules as required.

3. Documentation Standards

For CPT 45380, documentation has two jobs: (1) prove that colonoscopy-level service was performed (extent and quality), and (2) support that biopsy occurred and was clinically justified (findings/indication, site, and sampling). Because colonoscopy claims are frequently audited for extent (cecal intubation) and for screening conversion correctness, documentation should be structured and unambiguous. GI coding guidance and MAC articles are consistent that documentation must show what was done, where it was done, and why.

3.1 Minimum documentation elements (audit-relevant)

• Extent of insertion: Document cecal intubation (or anastomosis) and the landmark(s) used to confirm it (e.g., ileocecal valve, appendiceal orifice). If not reached, document the maximal extent and why the exam was incomplete.
• Indication: State the clinical reason for colonoscopy (symptom, abnormal test, surveillance indication). This should align with diagnosis coding strategy and payer coverage framing.
• Bowel preparation quality: Include a description of prep adequacy (e.g., excellent/good/fair/poor) and whether it limited detection or completion. Inadequate prep is a common justification for early repeat colonoscopy and a common audit point when frequency looks high.
• Findings: Describe lesions and mucosal abnormalities with location, size (when applicable), morphology, and clinical impression. When the colon appears normal but biopsies are taken (e.g., chronic diarrhea), explicitly document that biopsies were obtained for a specific diagnostic question.
• Biopsy details: Document that biopsy was performed and specify location(s) sampled. A precise count is not required for CPT selection because “single or multiple” is inherent, but location documentation is crucial for distinct-lesion billing and for medical necessity support.
• Specimen handling: Note specimen labeling and submission to pathology (e.g., “specimens sent to pathology in separate jars labeled ascending colon, sigmoid lesion”). This supports downstream reconciliation and, in disputes, supports the fact that biopsy occurred.

Incomplete exam decision point: If the colonoscopy is incomplete, documentation must allow the coder to determine whether the service should be reported as discontinued/reduced services under payer rules and whether the procedure is better represented by a colonoscopy family code with a modifier versus a different lower endoscopy code. The safest path is to document extent and reason clearly; then apply payer rules using MAC guidance and GI coding references.

3.2 Documentation to support distinct lesion billing

When biopsy is billed alongside another colonoscopy intervention (e.g., snare polypectomy), the record must clearly show that the biopsy was performed on a different lesion/site than the lesion treated by the more extensive intervention. Best practice is to document lesions separately with distinct location descriptors (e.g., “cecum: ulcerated lesion biopsied” and “sigmoid: pedunculated polyp removed by snare”). This narrative supports correct modifier use when allowed by NCCI and reduces the appearance of unbundling.

4. Screening-to-Diagnostic Conversion (33 vs PT) and Diagnosis Strategy

A practical coding reality is that many colonoscopies start as screening, then become diagnostic/therapeutic when tissue is sampled. From a CPT standpoint, once biopsy occurs, the procedure is described by 45380 (not a screening-only diagnostic colonoscopy code). From a payer-processing standpoint, the claim may still need to be identified as preventive intent to apply preventive cost-sharing rules, depending on payer type and policy. GI society guidance and Medicare contractor materials are the key references for correct modifier selection and claim strategy.

4.1 Commercial payers (modifier 33)

For many commercial plans, modifier 33 is used to indicate that the procedure was a preventive service when performed as a screening colonoscopy under preventive coverage rules, even if biopsy occurred. Preventive processing also typically depends on diagnosis coding that includes a screening diagnosis (e.g., Z12.11) in addition to any findings. The operational objective is consistency between intent (screening) and outcome (biopsy performed) so the payer processes the service under preventive benefits when applicable. GI coding guidance emphasizes that failing to use preventive modifiers correctly can cause inappropriate patient cost-sharing.

4.2 Medicare (modifier PT)

Medicare separates screening colonoscopy coverage from diagnostic colonoscopy coding. When a Medicare screening colonoscopy results in a biopsy, the claim is generally billed with the appropriate CPT code (e.g., 45380) and modifier PT to indicate a screening test that became diagnostic/therapeutic. Medicare contractor materials specifically address “screening converted to diagnostic/therapeutic” scenarios and are the most practical reference for how claims adjudicate.

Medicare beneficiary cost-sharing for screening colonoscopies is described in Medicare coverage materials. Coverage details and patient liability may differ depending on whether tissue is removed and on current policy implementation; therefore, correct PT usage and correct screening diagnosis strategy remain essential to trigger the intended Medicare processing pathway described in Medicare guidance.

4.3 Diagnosis strategy for converted screenings

In converted screening cases, include:

• Screening diagnosis consistent with the intent (commonly Z12.11 for average-risk screening; or high-risk/history codes as applicable).
• Finding/abnormality diagnosis that explains why a biopsy occurred (polyp/lesion/inflammation/other abnormal finding). If pathology is not yet known at claim submission, code based on the endoscopic finding or clinical impression documented at the time of procedure.

This dual-diagnosis approach reduces denial risk because it simultaneously supports preventive intent and medical necessity for biopsy. Medicare contractor and payer medical policy logic often hinges on whether the procedure line can be justified by a supported indication and whether screening conversion is clearly signaled.

5. Modifier Guidance and NCCI Bundling

Colonoscopy coding is modifier-sensitive because (a) multiple interventions can occur in one session, and (b) edits are common. The most authoritative baseline for bundling and modifier permissibility within the digestive system is the CMS NCCI Policy Manual. NCCI does not replace CPT instructions, but it operationalizes many bundling concepts and is frequently used in payer edits and audits.

5.1 Modifier 59 / X modifiers (distinct procedural service)

When biopsy (45380) is performed in the same session as a more extensive colonoscopy intervention (e.g., polypectomy), separate reporting may be appropriate only if the biopsy is performed on a separate lesion/site and the edit allows a modifier to bypass bundling. In those circumstances, modifier 59 (or a more specific “X” modifier when required by payer) may be used to communicate distinctness. The record must demonstrate distinct lesions clearly; modifiers should never be used to “force pay” when the biopsy is part of the same lesion treated by the more extensive service. NCCI policy is the anchor for this compliance principle.

5.2 Modifier 33 (commercial preventive) and PT (Medicare preventive conversion)

Use preventive modifiers to align claim processing with preventive intent when a screening colonoscopy becomes diagnostic/therapeutic due to biopsy. The correct modifier depends on payer type (commercial vs Medicare). GI society coding guidance and MAC articles describe practical application; use the payer-appropriate modifier consistently and ensure the diagnosis set supports screening intent plus biopsy reason.

5.3 Modifier 52 / 53 (reduced/discontinued services) for incomplete colonoscopy

Incomplete colonoscopy reporting is a common risk area because it affects both payment and future coverage intervals. When an exam is not completed to the cecum, the modifier choice depends on payer policy and whether a therapeutic service was performed before termination. Medicare contractor guidance on diagnostic/therapeutic colonoscopy and screening conversion provides the most practical baseline for Medicare claims behavior. Regardless of modifier selection, the documentation must clearly describe:

• how far the scope advanced,
• why the procedure was not completed, and
• what interventions (including biopsy) were performed before termination.

If these elements are not explicit, the claim becomes hard to defend in audit or appeal.

6. Billing & Payment Considerations (Facility/Professional, Multiple Endoscopy)

CPT 45380 is typically billed by the physician/endoscopist on the professional claim, and by the facility (hospital outpatient department or ambulatory surgery center) on the institutional claim when applicable. The procedure does not use imaging-style professional/technical modifiers (-26/-TC); instead, place-of-service and claim type determine the professional vs facility payment split. GI society coding guidance and payer processing policies shape how these claims are adjudicated and how cost-sharing is applied in screening conversion scenarios.

6.1 Medicare multiple endoscopy payment logic

When multiple endoscopy procedures are performed in the same session, Medicare applies a multiple endoscopy payment methodology that differs from simple “multiple procedure” reductions. This can produce payment results that look unusual if you expect a flat 50% reduction for the secondary procedure. Because this is a payment rule (not a coding rule), coders should not attempt to “code to the payment.” Instead, code based on documentation, then verify whether the payer applied the correct endoscopy methodology during payment reconciliation. Medicare contractor guidance on diagnostic/therapeutic colonoscopy and broader Medicare payment rules inform this behavior.

6.2 Screening coverage framework

Medicare’s public coverage guidance explains screening colonoscopy eligibility and patient liability constructs in plain language. Even when a screening converts to biopsy, correct coding/modifier strategy is required to ensure the claim processes in the intended coverage pathway. Medicare coverage guidance should be treated as the patient-facing summary; MAC billing articles provide the operational claim instructions that drive adjudication.

6.3 Medical policy behavior (commercial and Medicare Advantage)

Commercial and Medicare Advantage plans may apply medical policy criteria to determine whether a diagnostic colonoscopy with biopsy is medically necessary (and whether preauthorization is required). Large payer medical policies can also influence documentation expectations (e.g., when biopsy is considered necessary for suspected IBD or chronic diarrhea evaluation). While plan policy is not “law,” it often predicts claim review behavior and informs appeal strategy when denials occur.

7. Comparison Table: 45380 vs 45378 vs 45385

8. Real-World Coding Scenarios

Scenario 1: Screening colonoscopy converts to biopsy (commercial plan)

Setting: Office-based GI practice / ASC (commercial payer).
Service: Screening colonoscopy; small lesion sampled with cold forceps biopsy and sent to pathology.
Coding logic: Report 45380 because biopsy occurred. Apply the appropriate preventive modifier per payer policy (commonly -33 for commercial preventive intent) and include a screening diagnosis plus a finding/lesion diagnosis when documented. This aligns CPT description with preventive processing intent.
Documentation tip: State screening intent, cecal intubation, bowel prep quality, lesion location, and biopsy site(s).

Scenario 2: Snare polypectomy plus biopsy of a separate lesion (distinct lesion logic)

Setting: Facility-based colonoscopy (professional + facility claims).
Service: Snare polypectomy performed on a sigmoid polyp; separate suspicious ulcer in cecum biopsied.
Coding logic: Report the polypectomy code for the removed lesion and report 45380 for the biopsy only if the biopsy is on a separate lesion/site. Apply modifier 59 (or payer-preferred distinctness modifier) to 45380 when required by edits and supported by documentation. NCCI policy is the anchor for distinct-lesion reporting and modifier use.
Documentation tip: Separate lesion descriptions with explicit locations reduce denials and post-pay audit exposure.

Scenario 3: Medicare screening colonoscopy converts to biopsy

Setting: Medicare beneficiary (screening benefit).
Service: Screening colonoscopy; biopsy performed due to abnormal mucosal finding.
Coding logic: Report 45380 (biopsy performed) and append modifier PT to indicate screening colonoscopy converted to diagnostic/therapeutic, consistent with MAC guidance. Diagnosis strategy should reflect screening intent plus the abnormal finding prompting biopsy.
Documentation tip: Make screening intent explicit; document what prompted the biopsy and where it was taken.

Scenario 4: Incomplete colonoscopy with biopsy performed before termination

Setting: Diagnostic colonoscopy attempt with poor prep or obstruction.
Service: Scope advanced to transverse colon; biopsy taken of abnormal area in descending colon; procedure terminated due to safety/visualization limits.
Coding logic: Report the therapeutic colonoscopy code that reflects the intervention performed (biopsy) and apply the appropriate reduced/discontinued modifier according to payer policy and MAC guidance, supported by documentation of maximal extent, reason for termination, and biopsy site. Medicare contractor guidance on diagnostic/therapeutic colonoscopy is a practical reference for these situations.
Documentation tip: Explicitly document maximal insertion depth and reason for termination; this is the difference between a defensible reduced/discontinued claim and an audit vulnerability.

Scenario 5: Repeat colonoscopy in a short interval due to inadequate prep

Setting: Repeat procedure after inadequate prep on prior attempt.
Service: Initial colonoscopy incomplete due to inadequate preparation; repeat scheduled soon after to complete evaluation; biopsy performed on repeat exam.
Coding logic: The initial attempt must be coded in a manner that accurately reflects incomplete service per payer policy (to support early repeat coverage), and the repeat is coded based on what was performed at the repeat session (e.g., 45380 if biopsy is performed). Medical policy and coverage rules often scrutinize short-interval repeats, so documentation of inadequacy and necessity is essential.